Keyword: Johnson & Johnson
JLABS lands first ex-North America site in Shanghai, Sanofi's Dengvaxia situation quickly worsens in the Philippines, Astellas buys DMD biotech.
Merck's appeal to the Supreme Court has drawn in the U.S. Solicitor General, and the outcome could reverberate across the pharmaceutical industry.
Recent years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class med may still be on its way, one analyst says.
It’s an A-plus for J&J and Sanofi. The second annual Good Pharma Scorecard assigned both drugmakers perfect scores of 100% for trial transparency.
After three wins in cases over the risks of blockbuster blood thinner Xarelto, Bayer and Johnson & Johnson have encountered their first defeat.
J&J's Remicade fell victim to biosimilar competition in Europe and the U.S., but the copycats' impact has been quite different in the two regions.
It feels as though we say this every year, but it bears repeating: From CEOs and COOs to division chiefs and venture capital partners, women are taking the lead and making an impact all over the life sciences industry.
Pfizer is the smartest company in the Dow. That’s according to Talent Growth Advisors' annual assessment of the 30 companies that make up the Dow Jones Industrial Average.
Johnson & Johnson's string of talc wins has come to an end as a judge in Missouri upheld a $110 million verdict against the company.
Johnson & Johnson may eventually tire of shelling out Darzalex payments to Genmab and take matters into its own hands, one analyst says.